NIH imposes agency-wide ban on pharmaceutical consulting fees

The National Institutes of Health will ban all its employees from taking consulting fees from drug companies for at least a year, the Los Angeles Times reports today. Last December, the newspaper exposed how widespread the practice had become at the federal agency. In some cases, high-ranking NIH decision-makers were receiving consulting fees and stock options from the drug industry.